Helen I. Torley
2016
In 2016, Helen I. Torley earned a total compensation of $4.9M as President and Chief Executive Officer at Halozyme Therapeutics, a 5% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $595,448 |
|---|---|
| Option Awards | $1,800,037 |
| Salary | $645,000 |
| Stock Awards | $1,799,998 |
| Other | $9,592 |
| Total | $4,850,075 |
Torley received $1.8M in option awards, accounting for 37% of the total pay in 2016.
Torley also received $595.4K in non-equity incentive plan, $645K in salary, $1.8M in stock awards and $9.6K in other compensation.
Rankings
In 2016, Helen I. Torley's compensation ranked 1,694th out of 14,075 executives tracked by ExecPay. In other words, Torley earned more than 88.0% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,694 out of 14,075 | 88th |
Division Manufacturing | 577 out of 5,489 | 90th |
Major group Chemicals And Allied Products | 161 out of 1,895 | 92nd |
Industry group Drugs | 110 out of 1,538 | 93rd |
Industry Biological Products, Except Diagnostic Substances | 22 out of 279 | 92nd |
Source: SEC filing on March 24, 2017.
Torley's colleagues
We found four more compensation records of executives who worked with Helen I. Torley at Halozyme Therapeutics in 2016.
News
Halozyme Therapeutics CEO Helen Torley's 2021 pay rises 14% to $7.5M
March 25, 2022
Halozyme Therapeutics CEO Helen Torley's 2020 pay rises 11% to $6.5M
March 26, 2021
Halozyme Therapeutics CEO Helen Torley's 2019 pay rises 1% to $5.9M
March 20, 2020
Halozyme Therapeutics CEO Helen Torley's 2018 pay rises 12% to $5.8M
March 22, 2019